 | • レポートコード：MRC2108A071 • 出版社/出版日：Mordor Intelligence / 2021年7月26日 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：バイオ |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社は、生物学的安全性試験の世界市場規模が、2021年から2026年の間に年平均12.4％成長すると予測しています。本調査レポートは、世界の生物学的安全性試験市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（試薬・キット、器具、その他）分析、用途別（ワクチン＆治療薬、細胞＆遺伝子治療、血液＆血液ベース治療、その他）分析、試験別（無菌性試験、バイオバーデン試験、エンドトキシン試験、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会/将来の見通しなどを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・生物学的安全性試験の世界市場規模：製品別（試薬・キット、器具、その他） ・生物学的安全性試験の世界市場規模：用途別（ワクチン＆治療薬、細胞＆遺伝子治療、血液＆血液ベース治療、その他） ・生物学的安全性試験の世界市場規模：試験別（無菌性試験、バイオバーデン試験、エンドトキシン試験、その他） ・生物学的安全性試験の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Avance Biosciences、Cytovance Biologics、Eurofins Scientific、Lonza、Merck KGaA、Promega Corporation、Thermo Fisher Scientific、Toxikon、WuXi AppTec、Biomerieux SA） ・市場機会/将来の見通し |
The biological safety testing market is expected to witness a CAGR of 12.4% during the forecast period, 2021-2026.
With the emergence of COVID-19, many pharmaceutical and biotechnology companies began developing novel treatments and vaccines against COVID-19. These rising R&D activities impacted positively on the biological safety testing market studied. For instance, in March 2020, Regeneron and Sanofi initiated the development of their biologic Kevzara for the treatment of patients with COVID-19. Kevzara (Sarilumab), jointly developed by Regeneron and Sanofi, also inhibits the IL-6 pathway. Biological safety testing plays a major role in ensuring the purity of vaccines and other biological products. Thus, with the development of new treatment for COVID-19, the demand for biological safety testing has also increased.
Some of the major factors that are driving the market growth are rapidly growing pharmaceutical and biotechnology industries, along with increasing investments, and rising production of new biologics due to the high disease burden. For instance, in 2019, biologics accounted for six of the top-eight drugs in terms of revenue. Humira (adalimumab), which was developed by AbbVie for the treatment of rheumatoid arthritis, psoriasis, Crohn’s, and other autoimmune diseases, led to USD 19 billion sales, as per the Top 15 Best-selling Drugs of 2019 report. Humira was also the fastest-growing biological drug.
Further, the biotechnology-derived products or biologicals have effectively made their ways into various aspects of healthcare, including diagnoses, prevention, and treatments of diseases. However, there remain certain potential safety concerns, which generally arise from the manufacturing processes and complex biological and structural characteristics of these products. Therefore, these products needs detailed and systematic biological safety testing, that eventually enables the adequate assessment of safety, before any kind of clinical investigation. Hence, the market is expected to thrive over the forecast period.
However, the biological safety process is quite time consuming and complex which is expected to hinder the market growth.
Key Market Trends
Bioburden Testing Segment is Expected to Hold Significant Share in the Test Segment of the Market Over the Forecast Period
Bioburden Testing Segment is expected to hold a significant share in the test segment of the market over the forecast period. Organizations like the World Health Organization have also released instructions for health managers and health workers on required infrastructures and standard procedures for effective sterilization, and decontamination of medical devices. These factors are expected to increase the demand for proper sterilization, which is expected to boost the demand of Bioburden testing as it acts as an efficient tool in the validation of validation and revalidation of sterilization processes, assessment of the efficiency of cleaning processes, routine monitoring of manufacturing processes to ensure safety.
Bioburden testing is an integral part of validation and revalidation of sterilization processes, assessment of the efficiency of cleaning processes, routine monitoring of manufacturing processes, monitoring of raw materials, components, or packaging, and overall environmental monitoring programs. The high adoption rate, to determine bioburden limits in wide-ranging biologics and medical devices. Further, the development of new products in the market is expected to accelerate the market studied. For instance, in December 2019, the company has launched the BD Kiestra IdentifA system in Europe and Canada, that is used for microbial identification. It has incorporated automated sample processing steps that ensures accuracy and minimal error.
Furthermore, there are high bioburden and microbial contamination rates during pharmaceutical and biologics manufacturing, which is expected to drive government and private organizations to improve underlying biological safety practices. Hence, all these practices performed might drive the overall market.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America Dominates the Market and is expected to do the same in the forecast period. The United States is expected to contribute majorly to the market growth of this region. Due to the outbreak of COVID-19, the rising R&D activities related to the COVID-19 have impacted positively on the market growth.
The growth of the biological safety testing market in this region can be directly attributed to the growing biotechnology and pharmaceutical industries in the region. The high growth of these industries is further attributable to factors, such as innovative technologies and the presence of favorable government initiatives. Also, the emerging need for validation of drugs and devices process of manufacturing is expected to boost the demand for the market studied. According to the United States Food & Drug Administration (FDA) report, in 2019, the United States had about 4,676 manufacturing sites for drugs.
Additionally, the advanced healthcare infrastructure and rising R&D spending are expected to increase the revenue size further. According to the data of Pharmaceutical Research and Manufacturers of America (PhRMA), in the United States, about USD 83 billion were spent by the pharmaceuticalndustry on the R&D. Thus, this is expected to boost the market growth over the forecast period.
Competitive Landscape
The biological safety testing market is highly competitive and consists of a few major players. Companies, like Avance Biosciences, Cytovance Biologics, Eurofins Scientific, Lonza, Merck KGaA, Promega Corporation, Thermo Fisher Scientific, Toxikon, and WuXi AppTec, among others, hold a substantial share in the market.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growth in the Pharmaceutical and Biotechnology Industries, along with Increasing Investments
4.2.2 Rising Production of New Biologics due to High Disease Burden
4.3 Market Restraints
4.3.1 Time Consuming Approval Process
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Reagents and Kits
5.1.2 Instruments
5.1.3 Other Products
5.2 By Application
5.2.1 Vaccines and Therapeutics
5.2.2 Cellular and Gene Therapy
5.2.3 Blood and Blood-based Therapy
5.2.4 Other Applications
5.3 By Test
5.3.1 Sterility Tests
5.3.2 Bioburden Tests
5.3.3 Endotoxin Tests
5.3.4 Other Tests
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Avance Biosciences
6.1.2 Cytovance Biologics
6.1.3 Eurofins Scientific
6.1.4 Lonza
6.1.5 Merck KGaA
6.1.6 Promega Corporation
6.1.7 Thermo Fisher Scientific
6.1.8 Toxikon
6.1.9 WuXi AppTec
6.1.10 Biomerieux SA
7 MARKET OPPORTUNITIES AND FUTURE TRENDS